ThinkCyte, a Tokyo, Japan-based startup developing devices for the early detection of Leukemia and other diseases, received an investment from Toyoda Gosei Co., Ltd. (TOKYO:7282).
The amount of the deal was not disclosed. The investment was made in October 2023, through Toyoda Gosei’s Corporate Venture Capital Dept.
Founded in 2016 and led by CEO Waichiro Katsuda, ThinkCyte is a startup developing and commercializing cell analysis and sorting technology platform using AI-based cell image analysis for a broad spectrum of applications, including the early detection of leukemia and other diseases. The company’s technology also holds future promise for use in drug discovery.
FinSMEs
28/11/2023